Anne Rositch News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anne rositch. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anne Rositch Today - Breaking & Trending Today

World Cancer Day: How JHSPH Researchers are Confronting Cancer


The research in Groopman’s program involves the development and application of molecular biomarkers of exposure, dose and effect from environmental carcinogens, including naturally occurring agents in the diet as well as those produced as a result of cooking practices. A major emphasis of the research has been in the elucidation of the role of aflatoxins, a common contaminant of the food supply, in the induction of liver cancer in high-risk populations living in Asia and Africa. This work has led to the identification of a strong chemical-viral interaction between aflatoxin and the human hepatitis B virus in the induction of liver cancer. These biomarkers have also been used in many collaborative molecular epidemiology studies of liver cancer risk and recently employed to assess the efficacy of a number of chemopreventive agents in trials in high-risk aflatoxin-hepatitis B virus–exposed populations. This research is now being extended to develop genetic biomarkers of p53 mutat ....

United States , Elizabeth Platz , Susang Komen , Amber Dsouza , Anthony Leung , Annef Rositch , Anne Rositch , John Groopman , Joanna Cohen , Johns Hopkins , Greg Kirk , National Cancer Institute , Global Health , American Cancer Society , World Cancer Day , Cohort Study , World Cancer Report , Lung Disease , North America , North American , National Cancer , American Cancer , Patient Researcher , Great Divide , Bloomberg School Of Public Health , School Of Public Health ,

Research news tip sheet: Story ideas from Johns Hopkins Medicine


In a study in mice and human cells, Johns Hopkins Medicine researchers say that they have developed a tiny, yet effective method for preventing premature birth. The vaginally delivered treatment contains nanosized (billionth of a meter) particles of drugs that easily penetrate the vaginal wall to reach the uterine muscles and prevent them from contracting. If proven effective in humans, the treatment could be one of the only clinical options available to prevent preterm labor. The FDA has recommended removing Makena (17-hydroxyprogesterone caproate), the only approved medicine for this purpose, from the market.
The study was published Jan. 13, 2020, in the journal ....

United States , Anna Beavis , Elliott Haut , Michaele Newman , Anne Rositch , Marisol Martinez , Stephanie Wethington , Johns Hopkins , Rachel Butch , Us Centers For Disease , Johns Hopkins University School Of Medicine , Division Of Gynecologic Oncology , Hopkins Community Connection , Johns Hopkins Center , Johns Hopkins Bloomberg School Of Public Health , Canadian Medical Association Journal , American Cancer Society , Johns Hopkins Medicine , Science Translational , Laura Ensign , Johns Hopkins University School , Disease Control , Brandyn Lau , Johns Hopkins Bloomberg School , Public Health , Addressing Racial Disparities ,